SCHEMBL3525462

SCHEMBL3525462

O=C(O)CCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2c(c1)CCO2

nearest known ligand 0.67

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARG P37231 19/20 0.67
PPARD Q03181 14/20 0.67
PPARA Q07869 14/20 0.67
LYPLAL1 Q5VWZ2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3522366 0.94 PPARG (0.75) PPARGPPARDPPARA
SCHEMBL3527557 0.89 PPARG (0.57) PPARGPPARDPPARALYPLAL1
SCHEMBL3527035 0.86 PPARG (0.59) PPARGPPARDPPARA
SCHEMBL3528873 0.86 PPARG (0.62) PPARGPPARDPPARA
SCHEMBL3524742 0.85 PPARG (0.89) PPARGPPARDPPARA
SCHEMBL3523566 0.84 PPARG (0.89) PPARGPPARDPPARA
SCHEMBL3528250 0.82 PPARG (0.88) PPARGPPARDPPARA
SCHEMBL3524214 0.82 PPARG (0.52) PPARGPPARDPPARALYPLAL1
SCHEMBL27733797 0.82 PPARG (0.48) PPARGPPARDPPARA
SCHEMBL3526206 0.81 PPARG (0.68) PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP PPARG 1018/4885PPARD 677/4885PPARA 847/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG PPARG 3/4885PPARD 4/4885PPARA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.